CAD 1.62
(-7.43%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 FY | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Arch Biopartners Inc. | 1.98 Million CAD | 100.0% |
Covalon Technologies Ltd. | 26.59 Million CAD | 100.0% |
Hemostemix Inc. | - CAD | NaN% |
Universal Ibogaine Inc. | 1.07 Million CAD | 100.0% |
Kane Biotech Inc. | 148.98 Thousand CAD | 100.0% |
MedMira Inc. | 432.52 Thousand CAD | 100.0% |
Marvel Biosciences Corp. | - CAD | NaN% |
NervGen Pharma Corp. | - CAD | NaN% |